Imatinib administration in two patients with liver metastases from GIST and severe jaundice

Imatinib is the only effective and approved systemic therapy for the treatment of patients with advanced gastrointestinal stromal tumours (GISTs). Although metastases from GISTs most commonly involve the liver, yielding hyperbilirubinaemia, very few data on imatinib administration in subjects with j...

Descripción completa

Detalles Bibliográficos
Autores principales: De Pas, T, Danesi, R, Catania, C, Curigliano, G, de Braud, F
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394355/
https://www.ncbi.nlm.nih.gov/pubmed/14562006
http://dx.doi.org/10.1038/sj.bjc.6601282
_version_ 1782155396443537408
author De Pas, T
Danesi, R
Catania, C
Curigliano, G
de Braud, F
author_facet De Pas, T
Danesi, R
Catania, C
Curigliano, G
de Braud, F
author_sort De Pas, T
collection PubMed
description Imatinib is the only effective and approved systemic therapy for the treatment of patients with advanced gastrointestinal stromal tumours (GISTs). Although metastases from GISTs most commonly involve the liver, yielding hyperbilirubinaemia, very few data on imatinib administration in subjects with jaundice are available. We provide evidence that imatinib tolerability was not adversely affected by jaundice in two patients with advanced GIST.
format Text
id pubmed-2394355
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23943552009-09-10 Imatinib administration in two patients with liver metastases from GIST and severe jaundice De Pas, T Danesi, R Catania, C Curigliano, G de Braud, F Br J Cancer Clinical Imatinib is the only effective and approved systemic therapy for the treatment of patients with advanced gastrointestinal stromal tumours (GISTs). Although metastases from GISTs most commonly involve the liver, yielding hyperbilirubinaemia, very few data on imatinib administration in subjects with jaundice are available. We provide evidence that imatinib tolerability was not adversely affected by jaundice in two patients with advanced GIST. Nature Publishing Group 2003-10-20 2003-10-14 /pmc/articles/PMC2394355/ /pubmed/14562006 http://dx.doi.org/10.1038/sj.bjc.6601282 Text en Copyright © 2003 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical
De Pas, T
Danesi, R
Catania, C
Curigliano, G
de Braud, F
Imatinib administration in two patients with liver metastases from GIST and severe jaundice
title Imatinib administration in two patients with liver metastases from GIST and severe jaundice
title_full Imatinib administration in two patients with liver metastases from GIST and severe jaundice
title_fullStr Imatinib administration in two patients with liver metastases from GIST and severe jaundice
title_full_unstemmed Imatinib administration in two patients with liver metastases from GIST and severe jaundice
title_short Imatinib administration in two patients with liver metastases from GIST and severe jaundice
title_sort imatinib administration in two patients with liver metastases from gist and severe jaundice
topic Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394355/
https://www.ncbi.nlm.nih.gov/pubmed/14562006
http://dx.doi.org/10.1038/sj.bjc.6601282
work_keys_str_mv AT depast imatinibadministrationintwopatientswithlivermetastasesfromgistandseverejaundice
AT danesir imatinibadministrationintwopatientswithlivermetastasesfromgistandseverejaundice
AT cataniac imatinibadministrationintwopatientswithlivermetastasesfromgistandseverejaundice
AT curiglianog imatinibadministrationintwopatientswithlivermetastasesfromgistandseverejaundice
AT debraudf imatinibadministrationintwopatientswithlivermetastasesfromgistandseverejaundice

Ejemplares similares